293780.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:30):

Stats
Dzisiejszy wolumen	82 507.00
Średni wolumen	148 148
Kapitalizacja rynkowa	138.48B
EPS	KRW-200.39 ( 2023-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW10.92 (0.18%)

Wolumen Korelacja

Długi: -0.21 (neutral)

Krótki: -0.40 (neutral)

Signal:(39.427) Neutral

AptaBio Therapeutics Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AptaBio Therapeutics Inc. Korelacja - Waluta/Towar

0.55
( weak )

0.60
( weak )

-0.27
( neutral )

0.63
( weak )

-0.68
( moderate negative )

AptaBio Therapeutics Inc. Finanse

Annual	2023
Przychody:	KRW323.87M
Zysk brutto:	KRW-421.60M (-130.18 %)
EPS:	KRW-856.45

FY	2023
Przychody:	KRW323.87M
Zysk brutto:	KRW-421.60M (-130.18 %)
EPS:	KRW-856.45

FY	2022
Przychody:	KRW48.35M
Zysk brutto:	KRW37.21M (76.95 %)
EPS:	KRW-473.98

Financial Reports:

No articles found.

AptaBio Therapeutics Inc.

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.